# How did sermorelin compare with growth hormone in children?

Published November 17, 2026 · Updated November 17, 2026 · Data as of November 15, 2026

In a trial in children with hypothalamic growth hormone (GH) deficiency, mean height velocity was 14.6 cm/year on GH and 9.2 cm/year on low-dose [sermorelin](https://pepbank.io/p/sermorelin). [1] In the same trial, 20 of 20 children on high-dose sermorelin developed growth hormone-releasing hormone (GHRH) antibodies. So did 19 of 20 on the low dose. [1] PepBank's regulatory record shows US approval was withdrawn in 2009 because the maker stopped selling it. Safety and effectiveness were not the reason. [2]

## Key points

- In a trial in children with GH deficiency, mean height velocity was 14.6 cm/year on GH and 9.2 cm/year on low-dose sermorelin. [1]
- In the same trial in patients, growth did not differ significantly between the two sermorelin doses. [1]
- In a trial in patients, 20 of 20 children on high-dose sermorelin and 19 of 20 on low-dose sermorelin developed GHRH antibodies. [1]
- PepBank's regulatory record shows US approval of Geref was withdrawn in 2009 because the maker stopped selling it. [2]
- As of November 15, 2026, PepBank's trial registry records hold 0 registered trials that test sermorelin. [3]

## What was Geref and why did its US sale end?

The FDA approved Geref in 1990 for testing whether the pituitary gland can secrete growth hormone. [4] The FDA approved Geref in 1997 for idiopathic growth hormone deficiency in children with growth failure. [5]

PepBank's regulatory record shows US approval of Geref was withdrawn in 2009 because the maker stopped selling it. That record says the FDA found the withdrawal was not for safety or effectiveness reasons. [2]

Curo, a peptide shop with the same owner as PepBank, has a related article. [Peptide Clinical Trials in 2026: 890 Registered Studies Across 20 Compounds](https://curo.you/insights/peptide-clinical-trials-registry-count-2026)

## What happened in the 1993 trial in children?

A trial in 43 prepubertal children had hypothalamic growth hormone (GH) deficiency. In this trial, height velocity rose by 2 cm/year or more in all but two children. [6] In a trial in children with hypothalamic GH deficiency, growth on either sermorelin dose was significantly worse than on GH. [1]

In a trial in patients, mean height velocity was 9.2 cm/year on low-dose sermorelin and 9.3 cm/year on the high dose. On GH it was 14.6 cm/year. [1] Growth did not differ significantly between the two sermorelin doses in that trial in patients. [1]

The low dose was 30 micrograms/kg/day, given subcutaneously. It was a studied dose in people in a randomized controlled trial. [6] In that trial in patients, height velocity was lowest in the low-dose group. [6] Height SDS for bone age rose only in patients on GH. It did not rise on sermorelin. [6]

## How many children on sermorelin made antibodies?

In a trial in patients, all 20 children on high-dose sermorelin developed growth hormone-releasing hormone (GHRH) antibodies. On the low dose, 19 of 20 children did. [1]

## What did later trials in adults measure?

In a trial in healthy elderly men and women, a GHRH analog raised GH secretion by 107% and 70% within 4 weeks. The trial integrated the secretion over 12 h. [7] Serum IGF-I rose by 28% by 4 weeks in that trial in people and stayed high through 12 weeks. [7]

In a trial in age-advanced men and women, a GHRH analog raised serum IGF-I within 2 weeks. It stayed elevated for 12 weeks. [8] Serum IGFBP-3 also rose within 2 weeks in that trial in people, but IGFBP-1 did not. [8]

In a trial in adult survivors of childhood brain tumours, continuous GHRH amplified GH release in most people compared with spontaneous release. [9] That trial in people used a studied subcutaneous dose of 60 ng/kg/minutes in a randomized controlled trial. [9]

## What does PepBank hold on sermorelin?

As of November 15, 2026, PepBank holds 60 studies that gave sermorelin and reported results, with 304 results in total. [3] In [the sermorelin studies](https://pepbank.io/p/sermorelin/studies), PepBank holds 43 publications with findings in people. It also holds 10 with findings in animals and 7 with laboratory findings in cells or tissue. [3] The trial registry records in PepBank hold 0 registered trials that test sermorelin. [3]

Sermorelin is one of the [peptides in PepBank](https://pepbank.io/peptides), with 248 findings in people and 36 findings in animals. [3] The sermorelin record behind [sermorelin vs tesamorelin](https://pepbank.io/compare/sermorelin-vs-tesamorelin) holds 20 laboratory findings in cells or tissue and 0 findings predicted by a computer model. [3]

## What amounts were given in the trials in people?

The table lists studied amounts from trials in people. Each comes from a randomized controlled trial. [6, 7, 8, 9, 10]

| Kind | Dose | Species | Route | Design | Source |
| --- | --- | --- | --- | --- | --- |
| Studied dose | 30 micrograms/kg/day | people | subcutaneous | randomized controlled trial | [6] |
| Studied dose | 10 micrograms/kg | people | subcutaneous | randomized controlled trial | [7] |
| Studied dose | 10 microg/kg | people | subcutaneous | randomized controlled trial | [8] |
| Studied dose | 60 ng/kg/minutes | people | subcutaneous | randomized controlled trial | [9] |
| Studied dose | 10 micrograms | people | intravenous | randomized controlled trial | [10] |

## FAQ

### How quickly does sermorelin release growth hormone?

In a trial in age-advanced men and women, a nightly GHRH analog released growth hormone within 10 min, and the release lasted 2 h. The effect continued during the study. [8] In a randomized controlled trial in people, 10 adult male volunteers received a studied intravenous dose of 10 micrograms of GHRH(1-29)NH2. Their peak GH was significantly higher than with saline, at 24.03 mU/l. [10]

### Does sermorelin affect the immune system in older adults?

In a trial in healthy elderly men and women, a GHRH analog raised B cell responsiveness to mitogens by 50%. T cell responsiveness to phytohemagglutinin rose by 50% by 16 weeks. Lymphocytes with the IL-2 receptor (CD25) rose by 70% at 16 weeks. [7] The trial in people found no sex differences in the immune response, and T cell (CD3) numbers did not change. [7]

### Did sermorelin cause side effects in older adults?

In a trial in healthy elderly men and women, the researchers reported no adverse effects with a GHRH analog. [7] In a second trial in age-advanced men and women, the analog did not affect blood pressure or body weight. [8] In that trial in people, skin thickness rose significantly in both genders, with no other changes in body composition. [8]

## Sources

1. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993-03-01. https://pubmed.ncbi.nlm.nih.gov/8329830/ PMID 8329830. Evidence class: human.
2. Sermorelin: regulatory status in PepBank. PepBank, 2026-10-09. https://pepbank.io/p/sermorelin
3. Sermorelin in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/sermorelin
4. Geref (US). U.S. Food and Drug Administration (openFDA), 2026-10-09. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22SERMORELIN%22
5. Geref (US). U.S. Food and Drug Administration (openFDA), 2026-10-09. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22SERMORELIN%22
6. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993-03-01. https://pubmed.ncbi.nlm.nih.gov/8329826/ PMID 8329826. Evidence class: human.
7. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. The Journal of clinical endocrinology and metabolism, 1997-11-01. https://pubmed.ncbi.nlm.nih.gov/9360512/ PMID 9360512. Evidence class: human.
8. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 1997-05-01. https://pubmed.ncbi.nlm.nih.gov/9141536/ PMID 9141536. Evidence class: human.
9. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals. Clinical endocrinology, 1999-11-01. https://pubmed.ncbi.nlm.nih.gov/10594518/ PMID 10594518. Evidence class: human.
10. Low-dose growth hormone-releasing hormone tests: a dose-response study. European journal of endocrinology, 1994-09-01. https://pubmed.ncbi.nlm.nih.gov/7921207/ PMID 7921207. Evidence class: human.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/how-did-sermorelin-compare-with-growth-hormone-in-children

This is not medical advice.
